ALONX Stock Overview
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
Onxeo SA Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.30|
|52 Week High||€0.56|
|52 Week Low||€0.28|
|1 Month Change||-10.44%|
|3 Month Change||-10.44%|
|1 Year Change||-46.11%|
|3 Year Change||-50.25%|
|5 Year Change||-83.27%|
|Change since IPO||-97.71%|
Recent News & Updates
|ALONX||FR Biotechs||FR Market|
Return vs Industry: ALONX exceeded the French Biotechs industry which returned -56.8% over the past year.
Return vs Market: ALONX underperformed the French Market which returned -14.1% over the past year.
|ALONX Average Weekly Movement||5.4%|
|Biotechs Industry Average Movement||7.2%|
|Market Average Movement||4.8%|
|10% most volatile stocks in FR Market||8.9%|
|10% least volatile stocks in FR Market||2.7%|
Stable Share Price: ALONX is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALONX's weekly volatility (5%) has been stable over the past year.
About the Company
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Onxeo SA Fundamentals Summary
|ALONX fundamental statistics|
Is ALONX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALONX income statement (TTM)|
|Cost of Revenue||€416.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||-363.89%|
How did ALONX perform over the long term?See historical performance and comparison